Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Boehringer Ingelheim
Johnson and Johnson
Medtronic
McKesson

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Dexcel Pharma Company Profile

See Plans and Pricing

« Back to Dashboard

Summary for Dexcel Pharma
International Patents:12
US Patents:2
Tradenames:5
Ingredients:5
NDAs:6
Patent Litigation for Dexcel Pharma: See patent lawsuits for Dexcel Pharma

Drugs and US Patents for Dexcel Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dexcel Pharma LEVETIRACETAM levetiracetam TABLET, EXTENDED RELEASE;ORAL 202167-001 Sep 4, 2015 AB RX No No   Start Trial   Start Trial
Dexcel Pharma PERIOCHIP chlorhexidine gluconate TABLET;DENTAL 020774-001 May 15, 1998 RX Yes Yes   Start Trial   Start Trial
Dexcel Pharma LEVETIRACETAM levetiracetam TABLET, EXTENDED RELEASE;ORAL 202167-002 Sep 4, 2015 AB RX No No   Start Trial   Start Trial
Dexcel Pharma DONEPEZIL HYDROCHLORIDE donepezil hydrochloride TABLET;ORAL 203713-001 Feb 19, 2016 AB RX No No   Start Trial   Start Trial
Dexcel Pharma LANSOPRAZOLE lansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 208025-001 Jun 7, 2016 OTC No No   Start Trial   Start Trial
Dexcel Pharma OMEPRAZOLE omeprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 209400-001 Jul 5, 2017 OTC Yes No 10,076,494   Start Trial Y   Start Trial
Dexcel Pharma OMEPRAZOLE omeprazole TABLET, DELAYED RELEASE;ORAL 022032-001 Dec 4, 2007 OTC Yes Yes 9,023,391   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for DEXCEL PHARMA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03

International Patents for Dexcel Pharma Drugs

Supplementary Protection Certificates for Dexcel Pharma Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0124495 SPC/GB01/006 United Kingdom   Start Trial PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
1411900 2011/016 Ireland   Start Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
0162036 2000C/032 Belgium   Start Trial PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
1411900 SPC/GB11/015 United Kingdom   Start Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0296560 2/1998 Austria   Start Trial PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214
0984957 2012/048 Ireland   Start Trial PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
0162036 C300028 Netherlands   Start Trial PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Harvard Business School
Moodys
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.